Targeting angiogenesis is a well-established treatment strategy in a variety of tumor types, although for ovarian cancer, improvements in progression-free survival (PFS) have been modest. To improve their efficacy, combinations of antivascular agents may be considered. In this phase 1b/randomized phase 2 study, Morgan and colleagues evaluated pazopanib, an oral VEGFR inhibitor, with or without fosbretabulin, an intravenous vascular disrupting agent, in patients with advanced recurrent ovarian cancer.

Patients in the randomized phase 2 study (n = 21) received either 54 mg/m2 fosbretabulin and 600 mg/day pazopanib or 800 mg/day pazopanib alone. Median PFS was numerically greater for the fosbretabulin/pazopanib combination (7.6 months [95% confidence interval (CI), 4.1-not estimated]) than for the pazopanib alone group (3.7 months [95% CI, 1.0-8.1]; hazard ratio, 0.30; 95% CI, 0.08-1.03; P = .06). However, observed cardiac toxicity resulted in premature discontinuation of the trial, as 4 patients who received fosbretabulin/pazopanib (2 [16.7%] in phase 1b [n = 12], and 2 [9.5%] in the randomized phase 2 study) developed acute hypertension plus reversible secondary cardiac toxicity.

Although the fosbretabulin/pazopanib combination showed preliminary efficacy in treating recurrent epithelial ovarian cancer, reversible secondary cardiac toxicity associated with the treatment resulted in the premature discontinuation of the trial. The study investigators suggest that improved hypertension control may have prevented this toxicity.

Source

Morgan RD, et al. ESMO 2018. Abstract 956P.

Related Items
A Meta-Analysis to Evaluate the Risk for Fatigue in Patients Treated with Olaparib for Advanced Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018
The Efficacy of Apatinib Treatment for Advanced Ovarian Cancer After Second-Line Chemotherapy Failure
Conference Correspondent  published on October 22, 2018 in ESMO 2018
Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy for Recurrent Epithelial Ovarian Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018
Maintenance Olaparib Following Platinum-Based Chemotherapy in Newly Diagnosed Patients with Advanced Ovarian Cancer and a BRCA1/2 Mutation: Results from the Phase 3 SOLO1 Trial
Conference Correspondent  published on October 21, 2018 in ESMO 2018
A Phase 2 Trial of Combination Nivolumab and Bevacizumab in Recurrent Ovarian Cancer
Conference Correspondent  published on October 21, 2018 in ESMO 2018
Association of PD-L1 Expression with Clinical Response to Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer
Conference Correspondent  published on October 21, 2018 in ESMO 2018
A Phase 1/2 Study of Chemo-Immunotherapy with Durvalumab and Pegylated Liposomal Doxorubicin (PLD) in Platinum-Resistant Recurrent Ovarian Cancer
Conference Correspondent  published on October 20, 2018 in ESMO 2018
Meta-Analysis of PARP-Inhibitor–Associated Gastrointestinal and Hepatic Toxicities
Conference Correspondent  published on October 20, 2018 in ESMO 2018
Clinical Characteristics of Ovarian Cancer Relapse in BRCA1/2 Germ-Line Mutation Carriers and Noncarriers
Conference Correspondent  published on October 20, 2018 in ESMO 2018
A Phase 2 Study of Durvalumab, a PD-L1 Inhibitor, and Olaparib in Recurrent Ovarian Cancer
Conference Correspondent  published on October 20, 2018 in ESMO 2018
Last modified: October 22, 2018